Lupin Ltd.
NSE: LUPINLupin Ltd.: A 30-second snapshot
Lupin trades at a trailing PE of 20.74 (forward PE 23.59) with a trailing ROE of 26.91% and a quality score of 72, ranking 1st of 6 tracked pharma peers on PE, ROE, and quality score. Recent company-specific news is mixed: an FDA approval and a favorable plant inspection outcome sit alongside a product recall, against a backdrop of broader US generic-drug tariff coverage affecting the sector.
P/E
20.7
Forward P/E
23.6
ROE
+26.9%
Debt / Equity
29.39
Profit Margin
+19.1%
Div. Yield
+0.7%
5Y ROE > 15%
2/5
5Y FCF > 0
4/5
Quality
73/100
News
8 headlines · 3 positive · 3 negative
Lupin announces US FDA approval and launch of Sugammadex injection - Express Pharma
Express Pharma
Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy - PR Newswire
PR Newswire
Lupin recalls more than 2.5M prescription eye drop bottles, citing possible contamination - Fierce Pharma
Fierce Pharma
Lupin Receives USFDA EIR for New Jersey Plant with VAI Classification - Medical Dialogues
Medical Dialogues
Lupin, Sun Pharma to Cipla: Key pharma stocks that could be hit by Trump's tariffs plan on generic medicines import - livemint.com
livemint.com
Recent context
- ·US FDA approval and launch of a Sugammadex injection was reported on 2026-07-31 (Express Pharma)
- ·A recall of more than 2.5 million prescription eye-drop bottles over possible contamination was reported on 2026-07-13 (Fierce Pharma), alongside a USFDA Establishment Inspection Report for the New Jersey plant with VAI classification reported on 2026-07-03 (Medical Dialogues)
- ·Broader coverage in the same window discussed potential US tariffs on generic-drug imports, naming Lupin alongside Sun Pharma and Cipla as part of sector-wide reporting rather than a company-specific development
Strengths
- +Trailing ROE of 26.91% and quality score of 72 rank 1st of 6 tracked pharma peers, alongside a PE of 20.74 that is also the lowest in the peer set
- +5-year revenue growth of 31.9% and 5-year earnings growth of 89%
- +Free cash flow was positive in 4 of the years covered by the persistence dataset
- +Recent regulatory positives include US FDA approval and launch of a Sugammadex injection (Express Pharma, 2026-07-31) and a USFDA Establishment Inspection Report for the New Jersey plant with VAI classification (Medical Dialogues, 2026-07-03)
Weaknesses
- −Debt-to-equity trend is rising per the persistence data, even though the absolute level of roughly 0.29x remains low
- −ROE has been above 15% in only 2 of the years on record despite a current trailing ROE of 26.91%, with a consistency score of 69/100
- −A recall of more than 2.5 million prescription eye-drop bottles was reported over possible contamination (Fierce Pharma, 2026-07-13)
- −The quoted current price and moving averages do not carry an independent freshness timestamp for this run and news flow extends further into 2026 than the technical data appears to reflect
Open questions
- ?Does the rising debt trend reflect capacity expansion or working-capital needs, and how does it compare with the years of positive free cash flow in the same dataset?
- ?How does the eye-drop recall fit alongside the New Jersey plant's inspection outcome and the recent FDA product approval when looking at the company's overall regulatory compliance pattern?
- ?What explains only 2 of the tracked years showing ROE above 15% when the current trailing ROE stands at 26.91%?
- ?Given that 1-year price change is missing for all 5 peers and ROE is missing for Cipla, how much weight should the peer ranking of 1st of 6 on PE, ROE, and quality score carry?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| LUPIN | Lupin Ltd.You're viewing | 20.7 | +26.9% | 72 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹2,421.20
SMA 50
₹2,352.76
SMA 200
₹2,208.52
RSI (14)
51.3 (neutral)
From 52w high
-4.1%
1Y return
+24.4%
3M return
+4.1%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- mediumDebt-to-equity stands at roughly 0.29x, a low absolute level, but the persistence data show a rising debt trend across the historical record. ROE has been above 15% in only 2 of the years covered by the persistence dataset, despite a current trailing ROE of 26.91%, and free cash flow was positive in 4 of those years; the consistency score of 69/100 reflects this mixed pattern.
- mediumLupin recalled more than 2.5 million prescription eye-drop bottles over possible contamination (Fierce Pharma, 2026-07-13), a company-specific quality and regulatory item. Separately, US generic-drug tariff coverage in the same period named Lupin alongside Sun Pharma and Cipla as part of broader sector reporting rather than company-specific news.
- lowPeer comparison data is incomplete: 1-year price change is not available for any of the 5 tracked pharma peers, and ROE is missing for Cipla, limiting how much weight the peer rankings (Lupin ranks 1st of 6 on PE, ROE, and quality score) can carry.
- mediumThe technical section's current price of roughly Rs 2421.20 and moving averages do not carry an independent freshness timestamp for this run; given that news flow extends into late July 2026, this figure should be read as a data limitation rather than confirmed as of the 2026-08-01 run date.
Cross-section contradictions
- Lupin ranks 1st of 6 peers on PE, ROE, and quality score, and its available technical data show it above both the 50-day (Rs 2352.76) and 200-day (Rs 2208.52) moving averages after a 24.39% 1-year gain, yet the mean analyst rating sits at 2.49 across 37 analysts (1-5 scale, lower = more constructive) -- a mid-scale reading rather than a top-decile one relative to its peer-ranked and technical strength.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 1 Aug 2026 · rotates through NIFTY 500 every ~5 days